Get support for educating your patients about their condition and treatment.
Elliot G. Levy, MD, FACE Clinical Professor of Medicine
David S. Rosenthal, MD, FACP, FACE Long Island, New York
SYNTHROID® (levothyroxine sodium tablets, USP) is indicated as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter.
Management is important.
Help your patients identify possible symptoms of over- or under-treatment.
Whether you write your scripts or e-prescribe, make sure your patients get Synthroid in hand.
Thyroid hormones, including Synthroid, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
Please click here for full Prescribing Information
Full Prescribing Information |
Indication and Important Safety Information |
Site Map |
Contact Us |
© 2016 AbbVie Inc.